See more : Man Infraconstruction Limited (MANINFRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Talaris Therapeutics, Inc. (TALS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talaris Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- European Metals Holdings Limited (EMHXY) Income Statement Analysis – Financial Results
- Eshallgo Inc. Class A Ordinary Shares (EHGO) Income Statement Analysis – Financial Results
- SEKIDO Co., Ltd. (9878.T) Income Statement Analysis – Financial Results
- Union Petrochemical Public Company Limited (UKEM.BK) Income Statement Analysis – Financial Results
- Nevada Copper Corp. (NEVDF) Income Statement Analysis – Financial Results
Talaris Therapeutics, Inc. (TALS)
About Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.01M | 34.25M | 15.28M | 13.37M |
| General & Administrative | 19.47M | 13.26M | 7.41M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.47M | 13.26M | 7.41M | 5.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Cost & Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Interest Income | 900.00 | 0.00 | 400.00 | 200.00 |
| Interest Expense | 2.58M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.16M | 623.00K | 447.00K | 379.00K |
| EBITDA | -74.32M | -46.88M | -22.24M | -18.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.48M | -47.51M | -22.68M | -18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.58M | -326.00K | -23.00K | 223.00K |
| Income Before Tax | -73.89M | -47.83M | -22.71M | -18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.17M | 326.00K | 23.00K | -223.00K |
| Net Income | -68.73M | -48.16M | -22.73M | -17.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.66 | -16.53 | -34.00 | -28.09 |
| EPS Diluted | -16.66 | -16.53 | -34.00 | -28.09 |
| Weighted Avg Shares Out | 4.12M | 2.91M | 668.51K | 638.33K |
| Weighted Avg Shares Out (Dil) | 4.12M | 2.91M | 668.51K | 638.33K |
Talaris Therapeutics to Present at the 2022 Cell & Gene Meeting on the Mesa
BOSTON and LOUISVILLE, Ky., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics to Present at William Blair's Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
BOSTON and LOUISVILLE, Ky., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics to Participate in Two Upcoming Investor Conferences
BOSTON and LOUISVILLE Ky., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Shares of cell therapy concern Talaris Therapeutics crashed nearly 70% after GvHD outcomes in three Phase 3 trial kidney transplant patients were revealed at the end of June 2022. Even though its stock has essentially doubled off its update-induced low,...
Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study
BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood...
Talaris Therapeutics to Present at the Jefferies Healthcare Conference
BOSTON and LOUISVILLE, Ky., May 31, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics to Participate at Two Upcoming Investor Conferences
BOSTON and LOUISVILLE, Ky., March 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune disorders,...
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
BOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and...
Source: https://incomestatements.info
Category: Stock Reports